In-Vitro Dissolution & Biowaivers: Criteria, 12-Point Checklist, and Real-World Examples Designing Dissolution Methods That Win Biowaivers: Criteria, Checklist, and Examples Why Dissolution and Biowaivers Matter: Speed, Cost, and Regulatory Confidence In-vitro dissolution sits at the center of modern dossier strategy because regulators increasingly accept predictive laboratory evidence in place of in-vivo bioequivalence for certain products. A strong dissolution program can unlock BCS-based biowaivers for immediate-release small-molecule tablets/capsules, waive additional strengths once one strength is bridged in vivo, and provide ongoing post-approval control so you don’t repeat BE with every operational tweak. For US, UK, and EU filings, the technical and…

Q1/Q2 Sameness for ANDA: How FDA Evaluates Formulation Sameness and How to Prove It Proving Q1/Q2 Sameness in ANDAs: FDA Expectations and a Practical Evidence Strategy Why Q1/Q2 Sameness Matters: The Foundation of Therapeutic Equivalence Q1/Q2 sameness—also called formulation sameness—is central to the U.S. generic pathway. For many immediate-release, systemically acting small-molecule products, the Reference Listed Drug (RLD) sets the formulation blueprint. “Q1” means the same qualitative excipient list; “Q2” means closely matched quantitative levels for each excipient, typically within tight tolerances supported by function and performance data. FDA uses Q1/Q2 sameness as a practical proxy for pharmaceutical equivalence and…